Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Epigenomics AG announced the financial results for the year ended December 31, 2018.
Conference call and webcast, March 27, 2019 at 3pm CET (Frankfurt) / 10am EST (New York)
Genfit, with offices in Lille, France and Cambridge, Mass., launched its initial public offering (IPO) on the Nasdaq on March 27. Dean Hum, chief operating officer of Genfit, took time out to speak with BioSpace about the company, the IPO and elafibranor.
March has been a busy month for biopharma and medical device company initial public offerings. Here’s a look at the top IPO stories for the month.
The world-renowned HGH Infrared Systems is developing its brand image and communication strategy to better reflect its position as a global leader in the optronics market.
Soligenix, Inc announced its recent accomplishments and financial results for the year ended December 31, 2018.
YL Biolologics Ltd., Yoshindo Inc. and Teijin Ltd. have announced that on March 26, 2019, YL Biologics obtained manufacturing and sales approval for Etanercept biosimilar, an agent for anti-rheumatoid arthritis and polyarticular-course juvenile idiopathic arthritis which YL Biologics has developed globally.
Today, Celgene submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its ozanimod for adults with relapsing forms of multiple sclerosis (RMS).
Brammer has about 600 staffers at its primary locations in Massachusetts and Florida. The company was projected to bring in $250 million in revenue this year.
With some shareholder opposition raised against the $74 billion acquisition of Celgene, the BMS board of directors is attempting to strengthen support of the deal ahead of the April 12 meeting.